There could soon be a new treatment option for women diagnosed with an aggressive and difficult-to-treat form of breast cancer. Scientists at the Garvan Institute are beginning clinical trials with an experimental drug that's designed to make triple-negative breast cancer more responsive to chemotherapy.
There could soon be a new treatment option for women diagnosed with an aggressive and difficult-to-treat form of breast cancer. Scientists at the Garvan Institute are beginning clinical trials with an experimental drug that's designed to make triple-negative breast cancer more responsive to chemotherapy.
